Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 26 studies | 28% ± 10% | |
classical monocyte | 15 studies | 28% ± 9% | |
macrophage | 15 studies | 32% ± 15% | |
oligodendrocyte | 14 studies | 42% ± 15% | |
endothelial cell of lymphatic vessel | 12 studies | 28% ± 11% | |
non-classical monocyte | 12 studies | 24% ± 9% | |
microglial cell | 12 studies | 45% ± 19% | |
monocyte | 10 studies | 28% ± 9% | |
conventional dendritic cell | 10 studies | 24% ± 12% | |
dendritic cell | 10 studies | 29% ± 11% | |
ciliated cell | 8 studies | 25% ± 9% | |
myeloid cell | 8 studies | 32% ± 9% | |
vein endothelial cell | 8 studies | 29% ± 17% | |
oligodendrocyte precursor cell | 7 studies | 31% ± 12% | |
hematopoietic stem cell | 6 studies | 24% ± 8% | |
endothelial cell of vascular tree | 6 studies | 24% ± 9% | |
astrocyte | 6 studies | 28% ± 11% | |
natural killer cell | 5 studies | 17% ± 2% | |
mononuclear phagocyte | 5 studies | 29% ± 12% | |
GABAergic neuron | 5 studies | 33% ± 14% | |
epithelial cell | 5 studies | 36% ± 14% | |
basal cell | 5 studies | 23% ± 7% | |
hematopoietic precursor cell | 4 studies | 32% ± 10% | |
lymphocyte | 4 studies | 22% ± 4% | |
glutamatergic neuron | 4 studies | 47% ± 15% | |
brush cell | 4 studies | 68% ± 21% | |
goblet cell | 4 studies | 29% ± 12% | |
mast cell | 4 studies | 24% ± 3% | |
plasmacytoid dendritic cell | 4 studies | 19% ± 2% | |
common myeloid progenitor | 3 studies | 27% ± 15% | |
secretory cell | 3 studies | 21% ± 4% | |
endothelial cell of artery | 3 studies | 18% ± 1% | |
B cell | 3 studies | 22% ± 4% | |
alveolar macrophage | 3 studies | 31% ± 5% | |
interneuron | 3 studies | 34% ± 15% | |
renal alpha-intercalated cell | 3 studies | 24% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 5375.88 | 459 / 459 | 100% | 65.94 | 1118 / 1118 |
esophagus | 100% | 3911.69 | 1443 / 1445 | 100% | 40.17 | 183 / 183 |
intestine | 100% | 3363.99 | 966 / 966 | 100% | 39.47 | 526 / 527 |
lung | 100% | 3897.44 | 578 / 578 | 99% | 33.01 | 1149 / 1155 |
bladder | 100% | 3026.81 | 21 / 21 | 99% | 33.72 | 501 / 504 |
prostate | 100% | 2380.68 | 245 / 245 | 99% | 31.25 | 499 / 502 |
stomach | 100% | 3226.89 | 358 / 359 | 100% | 37.34 | 285 / 286 |
uterus | 100% | 2813.31 | 170 / 170 | 99% | 32.62 | 456 / 459 |
kidney | 100% | 3896.71 | 89 / 89 | 99% | 41.82 | 895 / 901 |
thymus | 100% | 2826.73 | 653 / 653 | 99% | 28.21 | 599 / 605 |
brain | 100% | 3708.41 | 2630 / 2642 | 99% | 28.55 | 698 / 705 |
ovary | 100% | 2307.34 | 180 / 180 | 98% | 22.23 | 422 / 430 |
skin | 100% | 3326.00 | 1809 / 1809 | 98% | 30.11 | 461 / 472 |
pancreas | 89% | 1214.00 | 292 / 328 | 99% | 35.71 | 176 / 178 |
adrenal gland | 100% | 3939.10 | 258 / 258 | 87% | 15.64 | 199 / 230 |
liver | 62% | 698.81 | 141 / 226 | 57% | 7.11 | 230 / 406 |
adipose | 100% | 5905.98 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 6703.12 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 36.03 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 26.10 | 1 / 1 |
blood vessel | 99% | 2040.52 | 1319 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 8171.57 | 915 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 97% | 22.91 | 28 / 29 |
eye | 0% | 0 | 0 / 0 | 95% | 24.48 | 76 / 80 |
heart | 94% | 1410.04 | 807 / 861 | 0% | 0 | 0 / 0 |
muscle | 69% | 750.09 | 554 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0030148 | Biological process | sphingolipid biosynthetic process |
GO_0006686 | Biological process | sphingomyelin biosynthetic process |
GO_1904504 | Biological process | positive regulation of lipophagy |
GO_0060612 | Biological process | adipose tissue development |
GO_0046512 | Biological process | sphingosine biosynthetic process |
GO_0046513 | Biological process | ceramide biosynthetic process |
GO_0046511 | Biological process | sphinganine biosynthetic process |
GO_0017059 | Cellular component | serine palmitoyltransferase complex |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0004758 | Molecular function | serine C-palmitoyltransferase activity |
GO_0030170 | Molecular function | pyridoxal phosphate binding |
Gene name | SPTLC2 |
Protein name | Serine palmitoyltransferase 2 (EC 2.3.1.50) (Long chain base biosynthesis protein 2) (LCB 2) (Long chain base biosynthesis protein 2a) (LCB2a) (Serine-palmitoyl-CoA transferase 2) (SPT 2) Alternative protein SPTLC2 Serine palmitoyltransferase long chain base subunit 2 |
Synonyms | LCB2 KIAA0526 |
Description | FUNCTION: Component of the serine palmitoyltransferase multisubunit enzyme (SPT) that catalyzes the initial and rate-limiting step in sphingolipid biosynthesis by condensing L-serine and activated acyl-CoA (most commonly palmitoyl-CoA) to form long-chain bases . The SPT complex is composed of SPTLC1, SPTLC2 or SPTLC3 and SPTSSA or SPTSSB. Within this complex, the heterodimer consisting of SPTLC1 and SPTLC2/SPTLC3 forms the catalytic core . The composition of the serine palmitoyltransferase (SPT) complex determines the substrate preference . The SPTLC1-SPTLC2-SPTSSA complex shows a strong preference for C16-CoA substrate, while the SPTLC1-SPTLC3-SPTSSA isozyme uses both C14-CoA and C16-CoA as substrates, with a slight preference for C14-CoA . The SPTLC1-SPTLC2-SPTSSB complex shows a strong preference for C18-CoA substrate, while the SPTLC1-SPTLC3-SPTSSB isozyme displays an ability to use a broader range of acyl-CoAs, without apparent preference . Crucial for adipogenesis (By similarity). . |
Accessions | H0YJ96 H0YJV2 ENST00000556607.1 L8E997 ENST00000216484.7 ENST00000554901.1 O15270 |